amprenavir has been researched along with AIDS Seroconversion in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bassetti, D; Castagna, A; De Pascalis, CR; Fusetti, G; Galli, A; Gianotti, N; Guffanti, M; Lazzarin, A; Seminari, E | 1 |
Berger, F; Jaeger, H; Kurowski, M; Mauss, S; Rockstroh, JK; Schmutz, G; Scholten, S; Wolf, E | 1 |
Gillotin, C; Lou, Y; Sadler, BM; Stein, DS | 1 |
Eron, JJ; Gillotin, C; Haubrich, R; Lang, W; Lou, Y; Sadler, BM; Stein, DS | 1 |
3 trial(s) available for amprenavir and AIDS Seroconversion
Article | Year |
---|---|
A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir.
Topics: Anti-HIV Agents; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Lopinavir; Prospective Studies; Pyrimidinones; Ritonavir; Sulfonamides | 2004 |
Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Dideoxynucleosides; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; RNA, Viral; Sulfonamides | 2001 |
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Topics: Adult; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Mixed Function Oxygenases; Nelfinavir; Orosomucoid; Saquinavir; Sulfonamides | 2001 |
1 other study(ies) available for amprenavir and AIDS Seroconversion
Article | Year |
---|---|
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.
Topics: Adult; Atazanavir Sulfate; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Outcome | 2003 |